Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech News Today.
Press releases published on June 2, 2025
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
GlobeNewswire
·
June 2, 2025
Presentation at the International Conference on Malignant Lymphoma (ICML) in Lugano on June 21 SIDNEY is an ongoing Phase 2 trial of EO2463 in 48 indolent Non-Hodgkin Lymphoma (iNHL) patients Enterome has held a positive Type-C meeting with FDA for …
Confluent Health Releases Groundbreaking Documentary to Tackle America’s Chronic Pain Crisis
GlobeNewswire
·
June 2, 2025
LOUISVILLE, Ky., June 02, 2025 (GLOBE NEWSWIRE) -- What if everything we thought we knew about pain was wrong? Today, more than 1 in 5 Americans live with chronic pain, and too often, their pain is met with silence, surgery, or a prescription pad. Now, …
Bitterroot Bio Announces Dosing of First Patient in MATADOR Phase 2a Study of BRB-002, an Immunomodulating Therapy Targeting CD47 in Atherosclerotic Cardiovascular Disease
GlobeNewswire
·
June 2, 2025
-Dosing initiated in proof-of-concept MATADOR Phase 2a study- -Initial results expected by year-end 2026- PALO ALTO, Calif. and NEEDHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Bitterroot Bio, a leader in developing innovative medicines in the field of …
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference
GlobeNewswire
·
June 2, 2025
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today …
SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
- ASCO Presentation Supports SLS009 as a Potential Targeted Therapy for ASXL1 Mutated Colorectal Cancer – - 22,500 New Cases of Colorectal Cancer with High Microsatellite Instability per Year in the US: 55% ASXL1m Frequency – NEW YORK, June 02, 2025 (GLOBE …
Sutro Biopharma Appoints Greg Chow as Chief Financial Officer
GlobeNewswire
·
June 2, 2025
SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of …
Xunlei Closes Acquisition of Hupu
GlobeNewswire
·
June 2, 2025
SHENZHEN, China, June 02, 2025 (GLOBE NEWSWIRE) -- Xunlei Limited ("Xunlei" or the "Company") (Nasdaq: XNET), a leading technology company providing distributed cloud services in China, today announced that it has closed the acquisition of Shanghai …
Humacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3
GlobeNewswire
·
June 2, 2025
DURHAM, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that its abstract on the V007 …
Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
GlobeNewswire
·
June 2, 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that the first patient has been dosed in the …
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference
GlobeNewswire
·
June 2, 2025
CONSHOHOCKEN, Pa., June 02, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) today announced that the company will participate in the 46th Annual Global Goldman Sachs Health Care Conference on Wednesday, June 11, 2025 at 10:40 A.M. …
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040
GlobeNewswire
·
June 2, 2025
ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited ( …
Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
GlobeNewswire
·
June 2, 2025
Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in …
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
GlobeNewswire
·
June 2, 2025
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) …
Bitmine Immersion Technologies, Inc. Announces Uplist to NYSE American Stock Exchange
GlobeNewswire
·
June 2, 2025
LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) -- Bitmine Immersion Technologies, Inc. (OTCQX: BMNRD) (“Bitmine” or “Company”), a technology company focused on Bitcoin mining using immersion technology, today announced that it expects its shares of common stock …
Stratus Therapeutics Strengthens Executive Team with Appointment of Michael P. Cooke, PhD as Chief Scientific Officer
GlobeNewswire
·
June 2, 2025
CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Stratus Therapeutics, Inc. (“Stratus”), a biotechnology company developing on-demand hematopoietic stem cell (HSC) therapies, today announced the appointment of Michael (Mike) P. Cooke, PhD, as Chief …
Calidi Biotherapeutics Presents systemic oncolytic platform with CD55-Enhanced expression and IL-15 Superagonist Payload at ASCO Annual Meeting
GlobeNewswire
·
June 2, 2025
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of systemic oncolytic targeted immunotherapies with the ability to deliver genetic …
Applied Digital Announces 250MW AI Data Center Lease With CoreWeave in North Dakota
GlobeNewswire
·
June 2, 2025
DALLAS, June 02, 2025 (GLOBE NEWSWIRE) -- Applied Digital Corporation (Nasdaq: APLD), a designer, builder and operator of next-generation digital infrastructure for HPC applications, has entered into two approximately 15-year lease agreements with …
Aqua Metals Announces Allowance of Foundational U.S. Patent for Lithium Battery Recycling Technology
GlobeNewswire
·
June 2, 2025
RENO, Nev., June 02, 2025 (GLOBE NEWSWIRE) -- Aqua Metals, Inc. (NASDAQ: AQMS), a leader in sustainable lithium battery recycling, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent …
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen
GlobeNewswire
·
June 2, 2025
45% overall response rate (ORR) and a 100% disease control rate (DCR) in HPV+ OPSCC patients treated with a median of 3 prior lines of therapy Marked unmet need exists in 2L+ HPV+ OPSCC patients; standard of care agents (methotrexate, docetaxel, or …
Celularity Announces Publication Advancing Ocular Surface Reconstruction with Tri-Layer Amniotic Membrane Technology
GlobeNewswire
·
June 2, 2025
Highlights the unique potential of Celularity’s proprietary advanced biomaterial technology as a novel cellular delivery system for ocular surface reconstruction Supports broad range of regenerative medicine applications beyond ophthalmology FLORHAM PARK, …